Cancer Diagnostics Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Description
Persistence Market Research has recently released a comprehensive report on the worldwide market for cancer diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global cancer diagnostics market from 2025 to 2032.
Key Insights:
Cancer Diagnostics Market Size (2025E): USD 137.8 Billion
Projected Market Value (2032F): USD 222.7 Billion
Global Market Growth Rate (CAGR 2025 to 2032): 7.1%
Cancer Diagnostics Market – Report Scope:
Cancer diagnostics encompass a wide range of tools, technologies, and procedures aimed at detecting cancer at early stages to improve treatment outcomes and survival rates. The market includes imaging technologies, biopsy techniques, tumor biomarkers, molecular diagnostics, and point-of-care testing systems. These diagnostics are utilized across hospitals, pathology labs, and specialty clinics to detect various types of cancer, including breast, lung, colorectal, prostate, cervical, and blood cancers. Market growth is driven by the rising global cancer burden, increasing awareness about early detection, and ongoing advancements in precision diagnostics and personalized medicine.
Market Growth Drivers:
The global cancer diagnostics market is propelled by multiple factors, notably the increasing incidence of cancer worldwide due to aging populations, lifestyle changes, and environmental factors. Early detection through advanced diagnostic technologies significantly improves survival rates, driving demand for innovative solutions. Technological advancements such as next-generation sequencing (NGS), liquid biopsy, and AI-powered diagnostic imaging are transforming cancer detection and facilitating minimally invasive approaches. Government initiatives supporting cancer screening programs, rising healthcare expenditure, and the growing adoption of companion diagnostics in oncology further stimulate market expansion.
Market Restraints:
Despite robust growth prospects, the cancer diagnostics market faces several challenges, including high diagnostic costs, especially for advanced molecular and genomic tests. Limited access to diagnostic facilities in low- and middle-income countries impedes early detection and treatment. Additionally, the complexity of cancer heterogeneity and evolving genetic mutations requires continuous innovation and clinical validation, raising development costs and time-to-market. Regulatory hurdles and reimbursement constraints also impact the commercial viability of emerging diagnostic technologies. Addressing these challenges necessitates cross-sector collaboration and targeted investment in affordable, scalable diagnostic platforms.
Market Opportunities:
The cancer diagnostics market presents significant growth opportunities driven by technological innovations and the expanding role of artificial intelligence and machine learning in diagnostics. The emergence of liquid biopsy as a non-invasive, real-time cancer monitoring tool is gaining traction. Growing investments in biomarker discovery, integration of big data analytics, and the development of multiplex diagnostic platforms open new avenues for personalized and early-stage cancer diagnostics. Moreover, increased focus on home-based cancer screening tools and mobile diagnostics can improve accessibility and compliance, especially in remote or underserved areas.
Key Questions Answered in the Report:
What are the key factors contributing to the global growth of the cancer diagnostics market?
Which diagnostic technologies and cancer types are driving market demand across various regions?
How are innovations in molecular diagnostics and AI reshaping the competitive dynamics of the market?
Who are the leading players in the cancer diagnostics market, and what strategies are they adopting for market leadership?
What are the emerging trends and future opportunities in the global cancer diagnostics landscape?
Competitive Intelligence and Business Strategy:
Leading players in the global cancer diagnostics market, such as F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, and Becton, Dickinson and Company, are actively investing in R&D, strategic collaborations, and acquisitions to enhance their diagnostic portfolios. These companies focus on developing comprehensive cancer detection platforms combining genetic, proteomic, and imaging-based technologies. Collaborations with pharmaceutical firms for companion diagnostics and personalized treatment regimens are key strategic moves. In addition, companies are expanding their geographic presence through partnerships with local healthcare providers and governments to address the rising demand for cancer diagnostics across emerging markets.
Key Companies Profiled:
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Abbott Laboratories
Illumina Inc.
bioMérieux SA
Qiagen
Siemens Healthineers
GE Healthcare
Hologic Inc.
Koninklijke Philips N.V. (Philips)
Agilent Technologies Inc.
Becton, Dickinson and Company (BD)
Myriad Genetics Inc.
AstraZeneca
Regeneron
Novartis
Bio-Rad Laboratories
Cancer Diagnostics Inc.
Quidel Corporation
Others
Market Segmentation
By Diagnostic Test
Biomarker Test
Prostate-Specific Antigen (PSA)
Circulating Tumor Cells (CTC)
Alpha-Fetoprotein (AFP)
Cancer Antigen 125 (CA-125)
HER2
Other
Imaging Technology
Magnetic Resonance Imaging (MRI)
Computed Tomography (CT)
Positron Emission Tomography (PET)
Mammography
Others
Endoscopy
Colonoscopy
Biopsy
Others
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Blood Cancer
Ovarian Cancer
Other
By End-Use
Hospitals
Diagnostic Laboratories
Cancer Research Institutes
Ambulatory Surgical Centers
By Region
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Key Insights:
Cancer Diagnostics Market Size (2025E): USD 137.8 Billion
Projected Market Value (2032F): USD 222.7 Billion
Global Market Growth Rate (CAGR 2025 to 2032): 7.1%
Cancer Diagnostics Market – Report Scope:
Cancer diagnostics encompass a wide range of tools, technologies, and procedures aimed at detecting cancer at early stages to improve treatment outcomes and survival rates. The market includes imaging technologies, biopsy techniques, tumor biomarkers, molecular diagnostics, and point-of-care testing systems. These diagnostics are utilized across hospitals, pathology labs, and specialty clinics to detect various types of cancer, including breast, lung, colorectal, prostate, cervical, and blood cancers. Market growth is driven by the rising global cancer burden, increasing awareness about early detection, and ongoing advancements in precision diagnostics and personalized medicine.
Market Growth Drivers:
The global cancer diagnostics market is propelled by multiple factors, notably the increasing incidence of cancer worldwide due to aging populations, lifestyle changes, and environmental factors. Early detection through advanced diagnostic technologies significantly improves survival rates, driving demand for innovative solutions. Technological advancements such as next-generation sequencing (NGS), liquid biopsy, and AI-powered diagnostic imaging are transforming cancer detection and facilitating minimally invasive approaches. Government initiatives supporting cancer screening programs, rising healthcare expenditure, and the growing adoption of companion diagnostics in oncology further stimulate market expansion.
Market Restraints:
Despite robust growth prospects, the cancer diagnostics market faces several challenges, including high diagnostic costs, especially for advanced molecular and genomic tests. Limited access to diagnostic facilities in low- and middle-income countries impedes early detection and treatment. Additionally, the complexity of cancer heterogeneity and evolving genetic mutations requires continuous innovation and clinical validation, raising development costs and time-to-market. Regulatory hurdles and reimbursement constraints also impact the commercial viability of emerging diagnostic technologies. Addressing these challenges necessitates cross-sector collaboration and targeted investment in affordable, scalable diagnostic platforms.
Market Opportunities:
The cancer diagnostics market presents significant growth opportunities driven by technological innovations and the expanding role of artificial intelligence and machine learning in diagnostics. The emergence of liquid biopsy as a non-invasive, real-time cancer monitoring tool is gaining traction. Growing investments in biomarker discovery, integration of big data analytics, and the development of multiplex diagnostic platforms open new avenues for personalized and early-stage cancer diagnostics. Moreover, increased focus on home-based cancer screening tools and mobile diagnostics can improve accessibility and compliance, especially in remote or underserved areas.
Key Questions Answered in the Report:
What are the key factors contributing to the global growth of the cancer diagnostics market?
Which diagnostic technologies and cancer types are driving market demand across various regions?
How are innovations in molecular diagnostics and AI reshaping the competitive dynamics of the market?
Who are the leading players in the cancer diagnostics market, and what strategies are they adopting for market leadership?
What are the emerging trends and future opportunities in the global cancer diagnostics landscape?
Competitive Intelligence and Business Strategy:
Leading players in the global cancer diagnostics market, such as F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, and Becton, Dickinson and Company, are actively investing in R&D, strategic collaborations, and acquisitions to enhance their diagnostic portfolios. These companies focus on developing comprehensive cancer detection platforms combining genetic, proteomic, and imaging-based technologies. Collaborations with pharmaceutical firms for companion diagnostics and personalized treatment regimens are key strategic moves. In addition, companies are expanding their geographic presence through partnerships with local healthcare providers and governments to address the rising demand for cancer diagnostics across emerging markets.
Key Companies Profiled:
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Abbott Laboratories
Illumina Inc.
bioMérieux SA
Qiagen
Siemens Healthineers
GE Healthcare
Hologic Inc.
Koninklijke Philips N.V. (Philips)
Agilent Technologies Inc.
Becton, Dickinson and Company (BD)
Myriad Genetics Inc.
AstraZeneca
Regeneron
Novartis
Bio-Rad Laboratories
Cancer Diagnostics Inc.
Quidel Corporation
Others
Market Segmentation
By Diagnostic Test
Biomarker Test
Prostate-Specific Antigen (PSA)
Circulating Tumor Cells (CTC)
Alpha-Fetoprotein (AFP)
Cancer Antigen 125 (CA-125)
HER2
Other
Imaging Technology
Magnetic Resonance Imaging (MRI)
Computed Tomography (CT)
Positron Emission Tomography (PET)
Mammography
Others
Endoscopy
Colonoscopy
Biopsy
Others
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Blood Cancer
Ovarian Cancer
Other
By End-Use
Hospitals
Diagnostic Laboratories
Cancer Research Institutes
Ambulatory Surgical Centers
By Region
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Table of Contents
180 Pages
- 1. Executive Summary
- 1.1. Global Cancer Diagnostics Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. COVID-19 Impact Analysis
- 2.4. Forecast Factors - Relevance and Impact
- 3. Value Added Insights
- 3.1. Value Chain Analysis
- 3.2. Diagnostic Test Adoption / Usage Analysis
- 3.3. Prevalence & Incidence of Cancer
- 3.4. Government Initiatives & Funding in Cancer Diagnostics
- 3.5. Key Market Players
- 3.6. Regulatory Landscape
- 3.7. PESTLE Analysis
- 3.8. Porter’s Five Force Analysis
- 3.9. Consumer Behavior Analysis
- 4. Global Cancer Diagnostics Market Outlook
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2032
- 4.3. Global Cancer Diagnostics Market Outlook Diagnostic Test
- 4.3.1. Historical Market Size (US$ Bn) Analysis, By Diagnostic Test, 2019-2023
- 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
- 4.3.2.1. Biomarker Test
- 4.3.2.1.1. Prostate-Specific Antigen (PSA)
- 4.3.2.1.2. Circulating Tumor Cells (CTC)
- 4.3.2.1.3. Alpha-Fetoprotein (AFP)
- 4.3.2.1.4. Cancer Antigen 125 (CA-125)
- 4.3.2.1.5. HER2
- 4.3.2.1.6. Other
- 4.3.2.2. Imaging Technology
- 4.3.2.2.1. Magnetic Resonance Imaging (MRI)
- 4.3.2.2.2. Computed Tomography (CT)
- 4.3.2.2.3. Positron Emission Tomography (PET)
- 4.3.2.2.4. Mammography
- 4.3.2.2.5. Others
- 4.3.2.3. Endoscopy
- 4.3.2.4. Colonoscopy
- 4.3.2.5. Biopsy
- 4.3.2.6. Others
- 4.3.3. Market Attractiveness Analysis: Diagnostic Test
- 4.4. Global Cancer Diagnostics Market Outlook Form
- 4.4.1. Historical Market Size (US$ Bn) Analysis, By Form, 2019-2023
- 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Form, 2024-2032
- 4.4.2.1. Isolates
- 4.4.2.2. Concentrates
- 4.4.2.3. Hydrolysates
- 4.4.3. Market Attractiveness Analysis: Form
- 4.5. Global Cancer Diagnostics Market Outlook Application
- 4.5.1. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2023
- 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
- 4.5.2.1. Lung Cancer
- 4.5.2.2. Breast Cancer
- 4.5.2.3. Prostate Cancer
- 4.5.2.4. Colorectal Cancer
- 4.5.2.5. Melanoma Cancer
- 4.5.2.6. Blood Cancer
- 4.5.2.7. Ovarian Cancer
- 4.5.2.8. Other
- 4.5.3. Market Attractiveness Analysis: Application
- 4.6. Global Cancer Diagnostics Market Outlook End-use
- 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2023
- 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
- 4.6.2.1. Hospitals
- 4.6.2.2. Diagnostic Laboratories
- 4.6.2.3. Cancer Research Institutes
- 4.6.2.4. Ambulatory Surgical Centers
- 4.6.3. Market Attractiveness Analysis: End-use
- 5. Global Cancer Diagnostics Market Outlook Region
- 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
- 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2032
- 5.2.1. North America
- 5.2.2. Latin America
- 5.2.3. Europe
- 5.2.4. East Asia
- 5.2.5. South Asia and Oceania
- 5.2.6. Middle East & Africa
- 5.3. Market Attractiveness Analysis: Region
- 6. North America Cancer Diagnostics Market Outlook
- 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 6.1.1. By Country
- 6.1.2. By Diagnostic Test
- 6.1.3. By Application
- 6.1.4. By End-use
- 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
- 6.2.1. U.S.
- 6.2.2. Canada
- 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
- 6.3.1. Biomarker Test
- 6.3.1.1. Prostate-Specific Antigen (PSA)
- 6.3.1.2. Circulating Tumor Cells (CTC)
- 6.3.1.3. Alpha-Fetoprotein (AFP)
- 6.3.1.4. Cancer Antigen 125 (CA-125)
- 6.3.1.5. HER2
- 6.3.1.6. Other
- 6.3.2. Imaging Technology
- 6.3.2.1. Magnetic Resonance Imaging (MRI)
- 6.3.2.2. Computed Tomography (CT)
- 6.3.2.3. Positron Emission Tomography (PET)
- 6.3.2.4. Mammography
- 6.3.2.5. Others
- 6.3.3. Endoscopy
- 6.3.4. Colonoscopy
- 6.3.5. Biopsy
- 6.3.6. Others
- 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
- 6.4.1. Lung Cancer
- 6.4.2. Breast Cancer
- 6.4.3. Prostate Cancer
- 6.4.4. Colorectal Cancer
- 6.4.5. Melanoma Cancer
- 6.4.6. Blood Cancer
- 6.4.7. Ovarian Cancer
- 6.4.8. Other
- 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
- 6.5.1. Hospitals
- 6.5.2. Diagnostic Laboratories
- 6.5.3. Cancer Research Institutes
- 6.5.4. Ambulatory Surgical Centers
- 6.6. Market Attractiveness Analysis
- 7. Europe Cancer Diagnostics Market Outlook
- 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 7.1.1. By Country
- 7.1.2. By Diagnostic Test
- 7.1.3. By Form
- 7.1.4. By Application
- 7.1.5. By End-use
- 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
- 7.2.1. Germany
- 7.2.2. France
- 7.2.3. U.K.
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Russia
- 7.2.7. Rest of Europe
- 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
- 7.3.1. Biomarker Test
- 7.3.1.1. Prostate-Specific Antigen (PSA)
- 7.3.1.2. Circulating Tumor Cells (CTC)
- 7.3.1.3. Alpha-Fetoprotein (AFP)
- 7.3.1.4. Cancer Antigen 125 (CA-125)
- 7.3.1.5. HER2
- 7.3.1.6. Other
- 7.3.2. Imaging Technology
- 7.3.2.1. Magnetic Resonance Imaging (MRI)
- 7.3.2.2. Computed Tomography (CT)
- 7.3.2.3. Positron Emission Tomography (PET)
- 7.3.2.4. Mammography
- 7.3.2.5. Others
- 7.3.3. Endoscopy
- 7.3.4. Colonoscopy
- 7.3.5. Biopsy
- 7.3.6. Others
- 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
- 7.4.1. Lung Cancer
- 7.4.2. Breast Cancer
- 7.4.3. Prostate Cancer
- 7.4.4. Colorectal Cancer
- 7.4.5. Melanoma Cancer
- 7.4.6. Blood Cancer
- 7.4.7. Ovarian Cancer
- 7.4.8. Other
- 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
- 7.5.1. Hospitals
- 7.5.2. Diagnostic Laboratories
- 7.5.3. Cancer Research Institutes
- 7.5.4. Ambulatory Surgical Centers
- 7.6. Market Attractiveness Analysis
- 8. East Asia Cancer Diagnostics Market Outlook
- 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 8.1.1. By Country
- 8.1.2. By Diagnostic Test
- 8.1.3. By Application
- 8.1.4. By End-use
- 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
- 8.2.1. China
- 8.2.2. Japan
- 8.2.3. South Korea
- 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
- 8.3.1. Biomarker Test
- 8.3.1.1. Prostate-Specific Antigen (PSA)
- 8.3.1.2. Circulating Tumor Cells (CTC)
- 8.3.1.3. Alpha-Fetoprotein (AFP)
- 8.3.1.4. Cancer Antigen 125 (CA-125)
- 8.3.1.5. HER2
- 8.3.1.6. Other
- 8.3.2. Imaging Technology
- 8.3.2.1. Magnetic Resonance Imaging (MRI)
- 8.3.2.2. Computed Tomography (CT)
- 8.3.2.3. Positron Emission Tomography (PET)
- 8.3.2.4. Mammography
- 8.3.2.5. Others
- 8.3.3. Endoscopy
- 8.3.4. Colonoscopy
- 8.3.5. Biopsy
- 8.3.6. Others
- 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
- 8.4.1. Lung Cancer
- 8.4.2. Breast Cancer
- 8.4.3. Prostate Cancer
- 8.4.4. Colorectal Cancer
- 8.4.5. Melanoma Cancer
- 8.4.6. Blood Cancer
- 8.4.7. Ovarian Cancer
- 8.4.8. Other
- 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
- 8.5.1. Hospitals
- 8.5.2. Diagnostic Laboratories
- 8.5.3. Cancer Research Institutes
- 8.5.4. Ambulatory Surgical Centers
- 8.6. Market Attractiveness Analysis
- 9. South Asia & Oceania Cancer Diagnostics Market Outlook
- 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 9.1.1. By Country
- 9.1.2. By Diagnostic Test
- 9.1.3. By Application
- 9.1.4. By End-use
- 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
- 9.2.1. India
- 9.2.2. Indonesia
- 9.2.3. Thailand
- 9.2.4. Singapore
- 9.2.5. ANZ
- 9.2.6. Rest of South Asia & Oceania
- 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
- 9.3.1. Biomarker Test
- 9.3.1.1. Prostate-Specific Antigen (PSA)
- 9.3.1.2. Circulating Tumor Cells (CTC)
- 9.3.1.3. Alpha-Fetoprotein (AFP)
- 9.3.1.4. Cancer Antigen 125 (CA-125)
- 9.3.1.5. HER2
- 9.3.1.6. Other
- 9.3.2. Imaging Technology
- 9.3.2.1. Magnetic Resonance Imaging (MRI)
- 9.3.2.2. Computed Tomography (CT)
- 9.3.2.3. Positron Emission Tomography (PET)
- 9.3.2.4. Mammography
- 9.3.2.5. Others
- 9.3.3. Endoscopy
- 9.3.4. Colonoscopy
- 9.3.5. Biopsy
- 9.3.6. Others
- 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
- 9.4.1. Lung Cancer
- 9.4.2. Breast Cancer
- 9.4.3. Prostate Cancer
- 9.4.4. Colorectal Cancer
- 9.4.5. Melanoma Cancer
- 9.4.6. Blood Cancer
- 9.4.7. Ovarian Cancer
- 9.4.8. Other
- 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
- 9.5.1. Hospitals
- 9.5.2. Diagnostic Laboratories
- 9.5.3. Cancer Research Institutes
- 9.5.4. Ambulatory Surgical Centers
- 9.6. Market Attractiveness Analysis
- 10. Latin America Cancer Diagnostics Market Outlook
- 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 10.1.1. By Country
- 10.1.2. By Diagnostic Test
- 10.1.3. By Application
- 10.1.4. By End-use
- 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
- 10.2.1. Brazil
- 10.2.2. Mexico
- 10.2.3. Rest of Latin America
- 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
- 10.3.1. Biomarker Test
- 10.3.1.1. Prostate-Specific Antigen (PSA)
- 10.3.1.2. Circulating Tumor Cells (CTC)
- 10.3.1.3. Alpha-Fetoprotein (AFP)
- 10.3.1.4. Cancer Antigen 125 (CA-125)
- 10.3.1.5. HER2
- 10.3.1.6. Other
- 10.3.2. Imaging Technology
- 10.3.2.1. Magnetic Resonance Imaging (MRI)
- 10.3.2.2. Computed Tomography (CT)
- 10.3.2.3. Positron Emission Tomography (PET)
- 10.3.2.4. Mammography
- 10.3.2.5. Others
- 10.3.3. Endoscopy
- 10.3.4. Colonoscopy
- 10.3.5. Biopsy
- 10.3.6. Others
- 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
- 10.4.1. Lung Cancer
- 10.4.2. Breast Cancer
- 10.4.3. Prostate Cancer
- 10.4.4. Colorectal Cancer
- 10.4.5. Melanoma Cancer
- 10.4.6. Blood Cancer
- 10.4.7. Ovarian Cancer
- 10.4.8. Other
- 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
- 10.5.1. Hospitals
- 10.5.2. Diagnostic Laboratories
- 10.5.3. Cancer Research Institutes
- 10.5.4. Ambulatory Surgical Centers
- 10.6. Market Attractiveness Analysis
- 11. Middle East & Africa Cancer Diagnostics Market Outlook
- 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 11.1.1. By Country
- 11.1.2. By Diagnostic Test
- 11.1.3. By Application
- 11.1.4. By End-use
- 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
- 11.2.1. GCC Countries
- 11.2.2. Egypt
- 11.2.3. South Africa
- 11.2.4. Northern Africa
- 11.2.5. Rest of Middle East & Africa
- 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
- 11.3.1. Biomarker Test
- 11.3.1.1. Prostate-Specific Antigen (PSA)
- 11.3.1.2. Circulating Tumor Cells (CTC)
- 11.3.1.3. Alpha-Fetoprotein (AFP)
- 11.3.1.4. Cancer Antigen 125 (CA-125)
- 11.3.1.5. HER2
- 11.3.1.6. Other
- 11.3.2. Imaging Technology
- 11.3.2.1. Magnetic Resonance Imaging (MRI)
- 11.3.2.2. Computed Tomography (CT)
- 11.3.2.3. Positron Emission Tomography (PET)
- 11.3.2.4. Mammography
- 11.3.2.5. Others
- 11.3.3. Endoscopy
- 11.3.4. Colonoscopy
- 11.3.5. Biopsy
- 11.3.6. Others
- 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
- 11.4.1. Lung Cancer
- 11.4.2. Breast Cancer
- 11.4.3. Prostate Cancer
- 11.4.4. Colorectal Cancer
- 11.4.5. Melanoma Cancer
- 11.4.6. Blood Cancer
- 11.4.7. Ovarian Cancer
- 11.4.8. Other
- 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
- 11.5.1. Hospitals
- 11.5.2. Diagnostic Laboratories
- 11.5.3. Cancer Research Institutes
- 11.5.4. Ambulatory Surgical Centers
- 11.6. Market Attractiveness Analysis
- 12. Competition Landscape
- 12.1. Market Share Analysis, 2024
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping by Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. F. Hoffmann-La Roche Ltd
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Sources
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Thermo Fisher Scientific Inc.
- 12.3.3. Abbott Laboratories
- 12.3.4. Illumina Inc.
- 12.3.5. bioMérieux SA
- 12.3.6. Qiagen
- 12.3.7. Siemens Healthineers
- 12.3.8. GE Healthcare
- 12.3.9. Hologic Inc.
- 12.3.10. Agilent Technologies Inc.
- 12.3.11. Becton, Dickinson and Company (BD)
- 12.3.12. Myriad Genetics Inc.
- 12.3.13. AstraZeneca
- 12.3.14. Regeneron
- 12.3.15. Novartis
- 12.3.16. BIO-RAD LABORATORIES
- 12.3.17. CANCER DIAGNOSTICS INC.
- 12.3.18. QUIDEL CORPORATION
- 12.3.19. Koninklijke Philips N.V. (Philips)
- 12.3.20. Others
- 13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
